Domestic leading pharmaceutical CRO service enterprises
•China's rapidly developing industrial pharmaceutical service providers of new drugs, generic drugs and preparations are accurately positioned at the core of the mid end of the CRO industry value chain, focusing on pre clinical CMC business and clinical business, and providing customers with one-stop professional pre clinical and clinical solutions.
•There are nearly 50000 square meters of standardized laboratories and 687 clinical bases in Beijing, Hainan, Shanghai, the United States, Australia and other places.The equipment and facilities rank second nationwide.It has an international top group scientist team, with 1300 technical team members, ranking the top three in the industry, of which 10% are employees with doctoral degree or above.
•It has a very strong customer acquisition ability. At present, there are more than 70 customers. Most of the top pharmaceutical enterprises in China are customers of the company.
•It is estimated that the contract order scale will exceed 2 billion yuan in 2021, and the operating revenue will reach 1.2 billion yuan. Calculated by revenue, ranking top in the industry;In terms of quantity, the pre clinical CMC business in 2019 has occupied the first place in China.
•In 2021, SciNova invested 50 million yuan to Huasky.